局部进展期胰腺癌治疗新进展—2009CSCO年会.pptVIP

可切除(resectable) T1-2 (OP w/o adjuvant) T1-2 (OP + Adjuvant CT) T3-4 (OP w/o adjuvant) T3-4 (OP + Adjuvant CT) 局部晚期(locally advanced) Borderline resectable (Neo-adjuvant + OP) 無法切除(unresectable) (Neo-adjuvant + OP) (ICT + CCRT) (Gem-based CT) (CCRT + CT) 轉移性(metastatic) // I I I I I I 5 10 15 20 25 30 27.6 19.1 50.2 20.5 14.0 14.3 18.0 20.5 13.0 11.0 7.0 ITT Per protocol Our data suggested inductional chemotherapy followed by CCRT could achieve encouraging survival in unresectable LAPC Role in earlier stage PC deserves further exploration 結論 * * * * * * * * * * * * * * * * * * * * * * * * * * This is a summary of survival data for pancreatic head adenocarcinoma from 4 major medical centers in Taiwan. The 5-y-s after cureative resection is 10% to 19.7o%, and 0% to 18.4% for palliative resection, but no 5-y-s for patients without resection. * * 局部進展期胰臟癌治療之新進展 陳立宗 M.D., Ph.D 國家衛生研究院 癌症研究所 國立成功大學附設醫院 血液腫瘤內科 高雄醫學大學附設醫院 胃腸內科 臺灣 Pancreas Liver GB Duodenum Liver Pancreas Stomach Duo A 胰臟癌 (Pancreatic Cancer) Adenocarcinoma of the exocrine pancreas Pancreas is a retro-peritonum organ Relatively symptom-free in early stage Early dissemination, small tumor does not have to early disease Easily metastasize to liver or encase great vessel Most common symptoms, obstructive jaundice, BW loss and back pain Usually diagnosed at advanced stage ＊ International Agency for Cancer Research. GLOBOCAN 2002. Available at: http://www-dep.iarc.fr. Accessed Septemberr 8th, 2009. Case No. Male Female Total (%) Global 124,841 10,465 232,306 (100.00) Asia 52,634 38,448 91,082 (39.21) North America 17,468 17,454 34,922 (15.03) South America 6,685 6,762 13,447 (5.79) Western Europe 10,603 9,803 20,406 (8.78) Eastern Europe 15,860 13,463 29,323 (12.62) Northern Europe 5,588 5,828 11,416 (4.91) Southern Europe 8,945 7,983 16,928 (7.29) Africa 3,647 3,768 7,41